Company / SG&A Expense
ANAPTYSBIO, INC SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$50.7M
FY2025
5-year range
$16.1M / $50.7M
FY2021-FY2025
Trend
+19.7%
vs FY2024
Sector context
#158 of 213
Health Care
What the data says
At $51M, ANAPTYSBIO, INC's sg&a expense ranks #56 of 213 in the Health Care sector. SG&A Expense has increased for 6 consecutive years, from $9M in FY2019 to $51M in FY2025.
Based on SEC 10-K filings.
$51M in FY2025 with a 5-year CAGR of +26.7%.
Increased from $42M to $51M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +39.1%
- 5-Year CAGR
- +26.7%
- 10-Year CAGR
- -
Sector benchmark
#56 of 213 in Health CareTop 26% of 213This company $50.7M Sector average $722.3M
▼
-93.0% below sector average
Key checks
Key Insights
- ANAPTYSBIO, INC's sg&a expense has grown for 6 consecutive years.
- 5-year CAGR of +26.7%, indicating consistent growth.
- In FY2025, sg&a expense increased 19.7% year-over-year.
- Ranks #158 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $50.7M | +19.7% |
| FY2024 | $42.4M | +1.1% |
| FY2023 | $41.9M | +122.5% |
| FY2022 | $18.9M | +17.1% |
| FY2021 | $16.1M | +3.7% |
| FY2020 | $15.5M | +66.3% |
| FY2019 | $9.3M | -39.9% |
| FY2018 | $15.5M | +332.6% |
| FY2017 | $3.6M | -16.3% |
| FY2016 | $4.3M | +19.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026